Studies of apoptosis in breast cancer

Marina Parton, Mitchell Dowsett, Ian Smith

Breast cancer is the commonest malignancy in women and comprises 18% of all cancers in women. The United Kingdom has the highest age standardised incidence and mortality from breast cancer in the world. Since 1990, death rates from breast cancer have decreased by over 25%, and this is at least in part due to the improved use of adjuvant tamoxifen and chemotherapy. Current research is focused on a greater understanding of the response and resistance to treatment, including the role of apoptosis. Accessibility of the primary tumour makes breast cancer uniquely suitable for such studies. Here we summarise and integrate the data on apoptosis and its role in the development, prognosis, and treatment of breast cancer.

Normal breast development is controlled by a balance between cell proliferation and apoptosis, and there is strong evidence that tumour growth is not just a result of uncontrolled proliferation but also of reduced apoptosis. The balance between proliferation and apoptosis is crucial in determining the overall growth or regression of the tumour in response to chemotherapy, radiotherapy and, more recently, hormonal treatments. All of these act in part by inducing apoptosis. Thus it is possible to delineate the biology of individual tumours at the molecular and biochemical level by examining apoptosis and its control and regulation and to exploit these to clinical advantage. Much of this work is still the subject of research. Understanding these relations could allow individually tailored treatments to maximise tumour regression and the efficacy of treatment. It could also help to answer why some tumours fail to respond and thereby indicate new routes of drug development.

Methods

We searched Medline with the keywords “human breast cancer” and “apoptosis.” We used our own collections of relevant articles and texts and our own experience of the specialty.

Detection and quantification of apoptosis in breast tissue

The gold standard for detection and quantification of apoptosis in situ has been by morphological assessment either with electron microscopy or light microscopy. Key features include chromatin condensation, nuclear fragmentation, cell shrinkage, and blebbing of the plasma membrane. However, such assessment is often difficult and time consuming, even for trained histopathologists, and therefore a variety of methods have been developed to ease the identification of these cells. The most widely used techniques concern the incorporation of labelled nucleotides on to the end of the large number of DNA fragments that occur in the late stages of apoptosis—for example, the TUNEL (terminal deoxynucleotidyl transferase mediated dUTP nick end labelling) assay

Summary points

- Increased apoptosis with increased proliferation is associated with malignant tumours
- Breast tumours with increased apoptosis are more likely to be high grade and negative for oestrogen receptors
- High levels of apoptosis in a breast tumour seem to predict worse survival
- Measurable increases in apoptosis occur within 24 hours of the start of chemotherapy

Why look at apoptosis in breast cancer?

Apoptosis plays a key part in the development of the normal breast.

- Dysregulation overrides many of the normal checkpoint pathways and leads to expansion of neoplastic cells
- Rates of apoptosis are related to tumour grade and more aggressive tumours have higher rates of apoptosis and proliferation
- Apoptosis is induced by chemotherapy, endocrine treatment, and radiotherapy; when these treatments fail, dysregulation of apoptosis may be a cause
- Genes and proteins that control apoptosis may become targets of manipulation to enhance the death of cancer cells

Breast cancer treated with neoadjuvant regimens (chemotherapy or endocrine treatment before surgery) provides ready access to tumours before and during treatment, enabling changes in apoptosis during treatment to be studied and correlated with response.
mitotic to apoptotic ratios as indices of overall cell death and proliferation in a tumour.

Apoptosis in the normal breast

The breast is one of the few organs that completes its development after birth in two discrete physiological states: puberty and pregnancy. During these stages there are noticeable alterations in breast proliferation and differentiation. Changes in the apoptotic regulatory proteins of the Bcl-2 family occur in part due to the influence of oestrogens and progesterone. Cells in the termini of the developing mammary ducts remain mitotically quiescent until the onset of pregnancy. Then rapid epithelial proliferation occurs, with additional ductal branching and lobuloalveolar growth. After lactation there is massive restructuring and apoptosis leading to involution and a return to the primary structure. In the absence of pregnancy there is repeated cycling of the resting state in parallel with menstruation until there follows a gradual process of senile involution with menopause. Most apoptotic changes occur in the lobular unit of the terminal duct, with cyclical changes through the menstrual cycle and a peak of apoptosis close to the end of the menstrual cycle. A peak of proliferation occurs a few days earlier. It is clear that a balance between proliferation, differentiation, and death of the cells throughout the mammary gland is critical for normal development and homeostasis. Situations that can upregulate cell proliferation or downregulate apoptosis may allow accumulation of mutations that result in breast cancer. Defects in the cellular processes that detect substantive damage to DNA and lead to the deletion of the cells can lead to the initial acquisition of these cancer related mutations.

Apoptosis studies in human breast cancer

Apoptosis in the history of breast cancer development

During carcinogenesis in epithelial tissue, genetic mutations accumulate and loss of cellular functions occur. The phenotype of the cells change from normal through a series of malignant lesions to superficial cancers and finally invasive disease (fig 2). In general these processes are protracted and are believed to occur up to 30 years before the clinical appearance of breast cancer. In the “premalignant” stages there are major alterations in apoptosis, proliferation, and regulatory biomarkers of the cell cycle.

Apoptosis is increased in ductal carcinoma in situ and invasive breast cancer. Apoptosis seems to be reduced relative to proliferation in “normal” breast...
Mitochondrial permeability and release of cytochrome C. Cell survival factors Bcl-2, Bcl-XL are involved in the mitochondrial pathway. Bax and Bid are cell death factors, which increase the permeability of the mitochondrial membrane and release cytochrome C. The released cytochrome C associates with caspase 9 in the cytoplasm and leads to its activation. activates caspase 9 in mitochondria. Apaf-1, a downstream mediator of apoptosis, is involved in the formation of the apoptosome, which initiates the caspase cascade.

Fig 3 Schematic representation of tumours responding or resistant to chemotherapy and associated changes in growth control.

Changes in apoptosis with chemotherapy
In models systems the established role of apoptosis in response to chemotherapy suggests that it is likely to be a good predictive or intermediate marker of breast cancer. Preoperative chemotherapy in early breast cancer allows a unique in vivo human model in which to study the changes in apoptosis that accompany and may determine the response to treatment. Biopsy samples (e.g., fine needle aspirates) taken before, during, and after preoperative chemotherapy can be examined for biomarkers or changes in biomarkers that may predict response, relapse, or survival. If a biomarker has a strong and persistent correlation with outcome then a clinician could see how effective a treatment has been and be guided to additional or alternative treatments.

Apoptosis related proteins in breast cancer and treatment
The core machinery of the pathway to cell death can be reduced to a few critical proteins that have been largely conserved throughout species. In humans these regulators exist as multigene families with many homologues that are individually expressed in various tissues. The Bcl-2 family (containing inhibitors and promoters of apoptosis) and the p53 tumour suppressor gene have been extensively studied in breast cancer. Figure 4 shows the relation between these oncogenes and proteins in the apoptotic pathways.

The Bcl-2 family of genes encodes proteins that may promote or inhibit apoptosis. Proapoptotic proteins include Bax, Bak, Bad, and Bcl-xL, whereas Bcl-2 and Bcl-xL are antiapoptotic. In humans Bcl-2 is expressed in about 80% of breast cancers and is correlated with the expression of oestrogen and progesterone receptors, and is a known poor prognostic indicator.
progesterone receptors—good prognostic features in breast cancer. This surprising association between an apoptosis inhibitor and good prognostic features is confirmed by the improved survival of patients with tumours that are Bcl-2 positive compared with those that are negative. Major correlations between Bax protein and outcome have not been observed, although studies have shown reductions in Bax to be associated with a poor response to chemotherapy in metastatic breast cancer. More recently BAG-1, a multifunctional protein that blocks apoptosis, has been correlated with improved survival in early stage breast cancer. Again, this seemingly contradictory finding in an inhibitor protein reflects the complex mechanisms in which these proteins work: BAG-1 is known to interact with other members of the Bcl-2 family as well as heat shock proteins and oestrogen receptors.

The protein product of p53 controls cellular functions involved in apoptosis, the cell cycle, and the repair of DNA. Mutations in this gene are the most common mutational event in cancer. Mutations in the gene or increased expression of the p53 protein (an indirect marker of mutation as this often results in stabilisation of the protein), has been associated with a poor prognosis to breast cancer in some studies. Chemotherapy, tamoxifen, and radiotherapy are known to induce apoptosis through p53 dependent and p53 independent pathways. Those studies that have measured mutation as opposed to protein over expression have consistently shown that mutated p53 is related to a poor response to chemotherapy. Response to tamoxifen does not seem to be consistently affected by the presence of mutant p53.

New biomarkers related to apoptosis that are being investigated include the caspases, proteolytic enzymes that form the principal intracellular effectors of apoptosis (the main "executioners of cell death"). So far 11 caspases have been identified in humans. Because caspases are synthesised as inactive zymogens that become activated by cleavage through an intracellular proteolytic cascade they can act as both initiators and effectors of the apoptotic pathway. Regulation of activation and activity occurs at several levels and in some cases involves antiapoptotic members of the Bcl-2 family, which block procaspases. Limited work has been carried out on these proteins in cancerous tissue from human breasts, but there is indication that caspases 3, 6, and 8 are associated with higher levels of apoptosis and histological grade. The recently identified family of genes that are inhibitors of apoptosis may also have major potential as predictive or prognostic biomarkers. These genes encode a group of proteins (XIAP, cIAP1, cIAP2, NAIP, and survivin in humans) that prevent apoptosis, in many cases by directly binding and inhibiting caspases. XIAP has emerged as one of the most powerful inhibitors and has been shown to be an adverse prognostic marker in acute myeloid leukaemia.

Future developments

A major goal of contemporary research into clinical breast cancer is to develop treatment regimens that are tailored to individual tumours and thereby maximise survival. Given that apoptosis is intimately involved in the response process, apoptosis and its controls are strong candidates for predictors and indices of response. So far the area is in its infancy as new biomarkers with greater potential are discovered and the complex interactions of the existing factors make interpretation of results difficult. The application of new microarray based approaches is likely to increase noticeably the number of candidate factors. The end result may well be a panel of biomarkers related to apoptosis that will profile the biology of an individual tumour and will enable clinicians to provide optimum treatment.

Preliminary work with targeted therapy with antisense oligonucleotides against the apoptosis inhibitors Bcl-2 and BclxL, have been carried out in vitro. New non-invasive techniques to measure apoptosis in the whole tumour are being developed using positron electron tomography and magnetic resonance spectroscopy. These may allow a more dynamic method of assessment as opposed to the snapshots afforded by biopsy.

Figure 2 is adapted with permission from original by Dr C Harper-Wynne.

Competing interests: None declared.

Problems with studies in apoptosis in breast cancer in humans

Current studies in apoptosis take a snapshot of a dynamic process; the half life of apoptotic cells in breast cancer is not known

Apoptotic bodies in tissue are the final product of a complex mechanism of cell death—many regulatory proteins are involved, and these may provide the key to control of induced cell death by chemotherapy

Many different methods are used to detect these biomarkers, and results are not always comparable

Only small numbers of patients in most of the studies are assessed, making the detection of the variable response to chemotherapy according to variation of apoptosis difficult

Prospective studies in which investigation of apoptotic changes is a primary or even a secondary end point are lacking

Monitoring of apoptosis during treatment currently involves serial biopsies of the breast cancer, an invasive procedure.

(Accepted 23 May 2001)

A memorable patient

Curtains for confidentiality

My memorable patient was not my patient, but while sharing a ward with her she taught me about privacy. I had already noticed her, pacing up and down the gynaecology ward. As she strutted to and fro, she stood out quite markedly from the other women sitting in bed knitting: she was very skinny, wore improbably high platform shoes and tight jeans, and had rather disorderly make up and hair.

"‘Ello,” she said as I slid further down under the covers in a vain attempt to avoid conversation. The track marks on her arms caught my eye. “I’m in ‘ere with gallstones. But it’s OK. They ain’t going to operatice. They’re going to wait for me to piss them out like normal. But I ain’t got nowhere to go, so they’re having to find me a place in an ‘ostel. Been working like normal. But I ain’t got nowhere to go, so they’re going to wait for me to piss them out and interprofessional discussions at the nursing station. After the tall, well muscled, shaven headed worker from the drug dependency unit had visited, I also knew the story behind her track marks.

She obviously had no idea that at least five other patients could hear every word of her conversations behind the curtain whether they wanted to or not. The patients could hear every word of her conversations behind the curtain whether they wanted to or not. They were a visual barrier that somehow, in the optimism of the imagination, also became impermeable to sound.

The nurses’ handover also rang out around the ward: an audible summary of every patient, updated daily. Then I realised that everyone must have heard all about me. I hoped that the finer points of medical jargon would have been lost on them. De Jong, van Deest, Baak, number of apoptotic cells as a prognostic marker in invasive breast cancer. Br J Cancer 1998;78:568-73.

A day came and went with its endless stream of abstracted doctors and others picking up notes and drawing the curtains around a bed for a clerking or private discussion with the patient. Soon I knew all about her real problems; it was impossible to avoid overhearing bedside consultations and interprofessional discussions at the nursing station. After the tall, well muscled, shaven headed worker from the drug dependency unit had visited, I also knew the story behind her track marks.

She obviously had no idea that at least five other patients could hear every word of her conversations behind the curtain whether they wanted to or not. The people who were talking to her also failed to realise that we could hear. The curtains seemed to provide some false sense of confidentiality. They were a visual barrier that somehow, in the optimism of the imagination, also became impermeable to sound.

The nurses’ handover also rang out around the ward: an audible summary of every patient, updated daily. Then I realised that everyone must have heard all about me. I hoped that the finer points of medical jargon would have been lost on them.

It was an affront: to basic human dignity, to privacy, to confidentiality. And it made me angry and rather ashamed that only now, 11 years out of hospital medicine, do I realise how many times on ward rounds, clerking patients, breaking bad news—particularly to deaf elderly patients—I must have thrown away any regard for confidentiality without even noticing it.

"‘Ere,” she said the next afternoon as she did her J Clin Oncol 2001;19:1588-69.


A memorable patient, A paper that changed my practice, My general practitioner, Notting Hill general practice, Annette Steele BMJ 2001;322:1532

Annette Steele: general practitioner, Notting Hill

We welcome articles up to 600 words on topics such as A memorable patient, A paper that changed my practice, My most unfortunate mistake, or any other piece conveying instruction, pathos, or humour. If possible the article should be supplied on a disk. Permission is needed from the patient or a relative if an identifiable patient is referred to. We also welcome contributions for “Endpieces,” consisting of quotations of up to 80 words (but most are considerably shorter) from any source, ancient or modern, which have appealed to the reader.

We welcome articles up to 600 words on topics such as A memorable patient, A paper that changed my practice, My most unfortunate mistake, or any other piece conveying instruction, pathos, or humour. If possible the article should be supplied on a disk. Permission is needed from the patient or a relative if an identifiable patient is referred to. We also welcome contributions for “Endpieces,” consisting of quotations of up to 80 words (but most are considerably shorter) from any source, ancient or modern, which have appealed to the reader.